Mallinckrodt has taken a major step toward hitting its goal of boosting revenues as much as 11% a year by announcing it would acquire Cadence Pharmaceuticals for $1.3 billion, or $14 a share, a 26% premium over Cadence's closing price yesterday.
The FDA has approved Cadence Pharmaceuticals' ($CADX) Ofirmev injection (acetaminophen) for the treatment of management of mild to moderate pain, the management of moderate to severe pain with
In a flurry of deals, California startup Incline Therapeutics has landed a $43 million Series A to back the development of a pain med delivery system and landed a $3.5 million upfront for an option
Shares of Cadence Pharmaceuticals (CADX) surged this morning after the developer said that it plans to resubmit its marketing application for the pain therapy Ofirmev within 30 days. Citing problems
Cadence Pharmaceuticals is ready to make regulatory submissions through the FDA's Electronic Submissions Gateway (ESG). The biopharma company worked with software provider ISI to implement its
The FDA has put Cadence Pharma's application to market its pain and fever therapy on hold. The agency alerted Cadence that it couldn't approve the drug--to be marketed as Ofirmev--until manufacturing
Saying it needs more time to evaluate pharmacological data, the FDA has extended the review period for Cadence Pharmaceuticals' Acetavance until February 2010. The original PDUFA data was today.
The FDA has granted Cadence Pharmaceuticals priority review for its Acetavance NDA. Acetavance (intravenous acetaminophen) is being reviewed for the treatment of acute pain and fever in adults and
Cadence Pharmaceuticals has submitted an NDA for Acetavance (intravenous acetaminophen), a potential treatment of acute pain and fever in adults and children. If approved, Acetavance would become the
In a new sign of a growing trend in biotechnology, Cadence Pharmaceuticals scored $86.6 million in a private placement of shares snapped up by a lengthy list of venture investors. In a deal